ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS

A securities class action lawsuit has been filed against Erasca, Inc. for allegedly making false and misleading statements about its lead oncology drug candidate ERAS-0015. The company and its executives are accused of improperly comparing their drug to a competitor's candidate while failing to disclose patent and trade secret disputes. Investors who purchased Erasca stock between January 14, 2025 and April 26, 2026 may be eligible for compensation, with a lead plaintiff deadline of August 10, 2026.